Simoctocog alfa for the treatment of hemophilia A
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2017.1391785
Abstract: ABSTRACT Introduction: Hemophilia A is the most frequent inherited bleeding disorder and most challenging coagulation disorder. To combat this, a number of new improved rFVIII/IX concentrates have recently been approved. Some of them are derived… read more here.
Keywords: simoctocog; alfa treatment; expert opinion; simoctocog alfa ... See more keywords
Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13625
Abstract: There are two major principles for coagulation factor replacement in the clinical management of surgical procedures in patients with haemophilia, repetitive bolus injections every 6‐12 hours or administration of coagulation factor concentrates by continuous infusion. read more here.
Keywords: alfa haemophilia; continuous infusion; haemophilia patients; infusion ... See more keywords
Successful of Immune Tolerance Induction (R-ITI) with Simoctocog Alfa (rhFVIII) in Hemophilia a Patients and High-Titer Inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114615
Abstract: Backgroud: The appearance of inhibitors (INH) is the most serious complication in hemophilia A (HA) patients. The primary objective is their eradication. Usually the primary ITI was performed with the same concentrate causing INH development,… read more here.
Keywords: inhibitor; treatment; alfa; simoctocog alfa ... See more keywords